Axcella Health has appointed William Hinshaw to serve as president and CEO. Before joining the Cambridge, MA, biotech company, Hinshaw was executive vice president and head of U.S. oncology for Novartis (NYSE: [[ticker:NVS]]). Axcella is developing protein drugs to address metabolic dysregulation. The company’s drug pipeline includes compounds for muscle, liver, and central nervous system disorders.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
